Veradermics, Inc (MANE) income statement
MANENYSEPharmaceutical PreparationsFiscal year ends December 31
$119.52−4.87 (-3.92%)
Close on Nov 20, 2026Market cap $4.99BP/E –Yield –
Veradermics, Inc financial ratios
See a number that looks wrong?
Close on Nov 20, 2026Market cap $4.99BP/E –Yield –
See a number that looks wrong?
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Returns on capital | |||
| Return on equity | 98.4% | 77.2% | – |
| Return on assets | -67.3% | -47.7% | – |
| Return on tangible assets | -67.3% | -47.7% | – |
| Return on capital employed | -74.5% | -52.7% | – |
| NOPAT | -$57.15M | -$21.15M | – |
| Cash flow quality | |||
| OCF / Net income | 1.02 | 0.89 | – |
| FCF / OCF | 100.0% | 100.0% | – |
| FCF / Net income | 1.02 | 0.89 | – |
| Unlevered free cash flow | -$71.63M | -$23.23M | – |
| Levered free cash flow | -$71.63M | -$23.69M | – |
| Efficiency | |||
| CapEx to OCF | -0.03% | -0.00% | – |
| Liquidity | |||
| Current ratio | 16.66 | 11.77 | – |
| Quick ratio | 16.66 | 11.77 | – |
| Cash ratio | 15.50 | 11.25 | – |
| Working capital | $143.34M | $50.82M | – |
| Net current asset value | $143.34M | $50.82M | – |
| Leverage | |||
| Assets to equity | -1.26 | -1.15 | – |
| Interest coverage | |||
| EBIT / Interest expense | – | -45.77 | – |
| Per share | |||
| EPS (basic) | -111.91 | -37.05 | – |
| EPS (diluted) | -111.91 | -37.05 | – |
| Book value per share | -161.40 | -65.79 | – |
| Tangible book value per share | -161.40 | -65.79 | – |
| Cash per share | 189.21 | 72.03 | – |
| Operating cash flow per share | -95.50 | -32.14 | – |
| Free cash flow per share | -95.53 | -32.14 | – |
| CapEx per share | 0.03 | 0.00 | – |
| Per employee | |||
| Total employees | 21 | 21 | 21 |
| Operating profit per employee | -$3.45M | -$1.28M | – |
| Net income per employee | -$3.33M | -$1.26M | – |
| Free cash flow per employee | -$3.41M | -$1.13M | – |
| Growth | |||
| EBIT 1Y growth | -170.2% | – | – |
| Net income 1Y growth | -164.3% | – | – |
| Diluted EPS 1Y growth | -202.1% | – | – |
| Operating cash flow 1Y growth | -202.3% | – | – |
| Free cash flow 1Y growth | -202.4% | – | – |
| Total assets 1Y growth | 174.8% | – | – |
| Total equity 1Y growth | -149.6% | -118.0% | – |
Every figure here is calculated from standardized financial statements — hover a row name for the formula — not reported by the company. Valuation multiples use the closing price at the end of that period, not today's price.